Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

New data on cardiac damage before and after AVR suggests earlier treatment may be beneficial

Patients with higher levels of extravalvular cardiac damage prior to TAVR or SAVR face a higher risk of dying within two years, according to new findings presented at EuroPCR 2022 in Paris.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR vs. surgery: A new look at 1-year outcomes among moderate-risk patients with severe, symptomatic AS

All-cause mortality after one year was 4.6% for the TAVR group and 6.6% for the SAVR group

ACC.22 kicked off on Saturday, April 2, in Washington, D.C.

VIDEO: Key technology trends in cardiology, as seen at ACC.22

American College of Cardiology President Edward T. A. Fry, MD, discusses his general takeaways on technology advances seen during ACC.22. 

Thumbnail

TAVR safe and effective for patients with mixed aortic valve disease

MAVD patients did face a higher risk of requiring a permanent pacemaker, researchers noted, though the reason for this trend remains unclear. 

CT-FFR before TAVR improves detection of coronary artery disease, limits invasive imaging exams

CT-FFR, which recently got a boost from the 2021 AHA/ACC chest pain guidelines, could play a key role for clinicians hoping to screen TAVR patients for coronary heart disease. 

Balloon valvuloplasty months after implantation is a safe and effective treatment option for patients with transcatheter heart valve (THV) dysfunction, according to a new analysis published in the Journal of the American College of Cardiology

Late balloon valvuloplasty safe and effective for patients with THV dysfunction

The median time from heart valve implantation to balloon dilatation was 4.6 months.

TAVR Medtronic Evolut EXPAND TAVR II Pivotal Trial,

Is TAVR a sensible choice for patients with moderate, symptomatic aortic stenosis? Medtronic aims to find out

The trial is expected to enroll up to 650 patients from as many as 100 different facilities throughout the world.

transcatheter aortic valve replacement (TAVR) procedure guided by CT fusion imaging on a patient with heart failure and a blood clot

Cardiologists and surgeons perform first TAVR using CT imaging guidance on HF patient with blood clot

“We believe this case is potentially groundbreaking," one interventional cardiologist said. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.